Cormorant Asset Management »

Mersana Therapeutics shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Mersana Therapeutics (MRSN) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Mersana Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Mersana Therapeutics held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Mersana Therapeutics by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $5.2M 2.6M 2.01
2024-03-31 $12M 2.6M 4.48
2017-12-31 $4.9M 296k 16.43
2017-09-30 $5.1M 296k 17.29
2017-06-30 $1.1M 80k 13.97

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Arcellx Common Stock (ACLX)
Vaxcyte (PCVX)
Longboard Pharmaceuticals In (LBPH)
Eyepoint Pharmaceuticals Com New (EYPT)
Rapport Therapeutics (RAPP)
Crinetics Pharmaceuticals In (CRNX)
Edgewise Therapeutics (EWTX)
Merus N V (MRUS)
Bridgebio Pharma (BBIO)
Insmed Com Par $.01 (INSM)
Newamsterdam Pharma Company Ordinary Shares (NAMS)
Janux Therapeutics (JANX)
Axsome Therapeutics (AXSM)

View all positions for Cormorant Asset Management

Top funds holding Mersana Therapeutics

EcoR1 Capital
Nextech Invest
VR Adviser
Bain Capital Life Sciences Investors
BlackRock
BlackRock
Vanguard Group
Citadel Advisors
Rock Springs Capital Management
State Street Corporation
Cormorant Asset Management
Silverarc Capital Management
Geode Capital Management
Jpmorgan Chase & Co
Morgan Stanley

View all funds holding Mersana Therapeutics